Goldman Sachs
ABOS icon

Goldman Sachs’s Acumen Pharmaceuticals ABOS Stock Holding History

Goldman Sachs’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Sell
183,927
-22,756
-11% -$56.2K ﹤0.01% 5709
2026
Q1 		$488K Buy
206,683
+88,832
+75% +$227K ﹤0.01% 5611
2025
Q4 		$249K Sell
117,851
-29,297
-20% -$58.1K ﹤0.01% 5953
2025
Q3 		$252K Sell
147,148
-187,535
-56% -$260K ﹤0.01% 5849
2025
Q2 		$388K Buy
334,683
+138,476
+71% +$149K ﹤0.01% 5312
2025
Q1 		$216K Sell
196,207
-22,937
-10% -$32.8K ﹤0.01% 5606
2024
Q4 		$377K Buy
219,144
+73,283
+50% +$176K ﹤0.01% 5390
2024
Q3 		$362K Buy
145,861
+94,809
+186% +$257K ﹤0.01% 5216
2024
Q2 		$124K Sell
51,052
-266,852
-84% -$850K ﹤0.01% 5375
2024
Q1 		$1.29M Buy
317,904
+203,172
+177% +$766K ﹤0.01% 4174
2023
Q4 		$441K Buy
114,732
+57,433
+100% +$170K ﹤0.01% 4832
2023
Q3 		$238K Buy
57,299
+43,727
+322% +$270K ﹤0.01% 4980
2023
Q2 		$65.3K Sell
13,572
-28,730
-68% -$138K ﹤0.01% 5429
2023
Q1 		$172K Buy
42,302
+25,311
+149% +$132K ﹤0.01% 5347
2022
Q4 		$91.8K Sell
16,991
-5,626
-25% -$37.8K ﹤0.01% 5500
2022
Q3 		$227K Sell
22,617
-5,269
-19% -$30.2K ﹤0.01% 5425
2022
Q2 		$131K Sell
27,886
-306,309
-92% -$1.15M ﹤0.01% 5776
2022
Q1 		$1.31M Buy
334,195
+10,931
+3% +$59.5K ﹤0.01% 4608
2021
Q4 		$2.19M Buy
323,264
+259,629
+408% +$2.85M ﹤0.01% 4179
2021
Q3 		$946K Buy
+63,635
New +$1.06M ﹤0.01% 4788

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Goldman Sachs's ABOS Position: Q2 2026 in Review

Goldman Sachs reduced its Acumen Pharmaceuticals (ABOS) stake by 11% in Q2 2026, selling an estimated $56.2K and leaving 183,927 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #5709.

Goldman Sachs first reported a position in ABOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.19M in Q4 2021. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Goldman Sachs held 183,927 shares of Acumen Pharmaceuticals worth $491K as of Q2 2026.
  • Goldman Sachs sold 22,756 Acumen Pharmaceuticals shares in Q2 2026, an estimated $56.2K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5709 holding.
  • Goldman Sachs first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Goldman Sachs's Acumen Pharmaceuticals position peaked at $2.19M in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.